Les Laboratoires Servier
http://www.servier.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Les Laboratoires Servier
InflaRx Undaunted By Dermatology Rivals
The group says INF904 can make billions in two highly competitive skin diseases, but this looks optimistic.
Agios Extends Cash Runway With $905m Royalty Pharma Deal
Deal Snapshot: Agios sold rights to a 15% royalty on US net sales of the IDH1/2 inhibitor vorasidenib, which it sold to Servier in 2020.
Verastem RAMPS Up In Rare Ovarian Cancer With Avutometinib/Defactinib Filing
The company announced topline data from the RAMP 201 trial in low-grade serous ovarian cancer, a rare disease with no FDA-approved treatments, and started a rolling FDA submission.
Glioblastoma Market Snapshot: Two Approvals In 2024 And A Rich Pipeline
Glioblastoma carries a grim prognosis. The biopharma industry is trying to improve patient outcomes, with 120 drugs in the pipeline and two anticipated approvals this year.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Generic Drugs
-
Biotechnology
- Gene Therapy, Cell Therapy
- Other Names / Subsidiaries
-
- Biogaran SAS
- Egis Pharmaceuticals plc
- WeHealth
- Servier BioInnovation
- Symphogen A/S
- Servier Pharmaceuticals, LLC.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice